Table 2.

Demographics, disease, treatments and types and severity of toxicity reported in the 11 cases of the present study.

Case	Demographics	Disease	Treatment	Enterocolitis	Neutropenia	Mucositis or Stomatitis	Diarrhoea	Emesis	Cutaneous toxicity	Anorexia	Asthenia
1	65-year-old male	Colon adenocarcinoma	FOLFOX (5-FU)	IV
2	46-year-old woman	Breast carcinoma	XELOX (Capecitabine)	III	IV
3	55-year-old woman	Gastric adenocarcinoma	5-FU, epirubicin, cisplatin			IV	IV	IV
4	78-year-old woman	Colon adenocarcinoma	Capecitabine	III		III		III
5	47-year-old woman	Rectal adenocarcinoma	XELOX (Capecitabine)	III
6	79-year-old woman	Gastric adenocarcinoma	XELOX (Capecitabine)			III	III	III
7	67-year-old woman	Colon adenocarcinoma	Capecitabine	III					III
8	69-year-old woman	Anal adenocarcinoma	5-FU and cisplatin			III
9	71-year-old woman	Breast carcinoma	Capecitabine							III	III
10	52-year-old male	Colon adenocarcinoma	FOLFOX (5-FU)		III
11	71-year-old woman	Breast carcinoma	Capecitabine				IV	IV

Toxicity severity is shown according to the Common Terminology Criteria for Adverse Events (CTCAE) scale.